SCODiA Report by MLBI Lab

Single-Cell Transcriptomic and Genomic Profiling of Human Colon Cancer Reveals Tumor Microenvironment Remodeling and Novel Therapeutic Targets

This report details a comprehensive single-cell analysis of human colon tissue, comparing normal and tumor conditions. Key findings include the identification of Intestinal Epithelial cells as the tumor-origin cell type, exhibiting widespread aneuploidy and dysregulated cell cycle activity. The tumor microenvironment is significantly remodeled, characterized by shifts in immune cell populations such as an increase in immunosuppressive regulatory T cells and pro-tumorigenic M2 macrophages, alongside the activation of cancer-associated fibroblasts. Cell-cell communication patterns are drastically altered, with a loss of beneficial immune crosstalk and emergence of new immune checkpoint interactions. These insights illuminate disease mechanisms and pinpoint promising therapeutic targets within both tumor cells and the surrounding microenvironment.

Contents

  1. Dataset overview
  2. UMAP Visualization of Cellular Composition and Ploidy Status in Colon Tissue
  3. Major Cell Type Score and Ploidy Visualization on UMAP
  4. Marker Expression Dot Plot for Cell Subsets
  5. Copy Number Variation (CNV) Analysis of Intestinal Epithelial Cells in Colon Cancer
  6. CNV-based UMAPs for Cell Type, Ploidy, Condition, and Sample Distribution
  7. Minor Cell Type Population Analysis Across Normal and Tumor Colon Samples
  8. T Cell Subset Population Analysis in Normal and Colon Tumor Samples
  9. Differential Abundance of T cell and Immune Cell Subsets in Colon Cancer
  10. Macrophage Subset Population Analysis in Colon Normal and Tumor Tissues
  11. Differential Abundance of Macrophage Subsets in Colon Cancer
  12. Ploidy Status of Intestinal Epithelial Cells in Normal and Tumor Conditions
  13. Cell-Cell Interaction Landscape Alterations in Colon Cancer
  14. Immune Checkpoint and Cell Cycle Pathway Cell-Cell Interactions in Colon Tissue
  15. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
  16. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers
  17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
  18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue
  19. Differential Expression of Cell Cycle Genes in Intestinal Epithelial Cells in Colon Cancer
  20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells
  21. Gene Set Enrichment Analysis of Colon Cancer Cell Types
  22. Discussion
  23. Query List

0. Dataset overview

Dataset Summary

Available Annotations (obs columns):

Precomputed Results:

Inferred Disease/Biological Context

1. UMAP Visualization of Cellular Composition and Ploidy Status in Colon Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots generated from single-cell RNA-seq data, visualizing the distribution of cells based on various metadata annotations: condition (normal vs. tumor), sample origin, major cell type, minor cell type, ploidy status, and cell type subset. The primary goal is to provide an overview of the dataset's structure, cell type identities, and how conditions and ploidy status relate to the overall cellular landscape. Given the data context of colon tissue with normal and tumor conditions and identified aneuploidy, this visualization is crucial for understanding the cellular heterogeneity and identifying potential malignant populations.

Visual Summary

The UMAP plots reveal several distinct clusters and gradients, indicating diverse cell populations within the dataset.

Biological Interpretation

The UMAP visualizations provide robust evidence for the cellular composition and structural organization of the colon single-cell RNA-seq dataset, particularly in the context of colon cancer.

  1. Identification of Malignant Epithelial Cells: The most striking finding is the clear spatial separation of 'Aneuploid' cells within the UMAP. These cells are almost exclusively found in a single, large cluster that also consists predominantly of 'Intestinal Epithelial cells' and is highly enriched for cells from 'tumor' conditions. This observation strongly supports the resolution of 'Intestinal Epithelial cell' as the tumor-origin cell type and confirms the presence of a distinct malignant epithelial cell population characterized by aneuploidy, a hallmark of cancer progression PubMed search: aneuploidy in colon cancer.
  2. Tumor Microenvironment Heterogeneity: While the malignant epithelial cells form a distinct cluster, other cell types, including various immune cells (T cells, B cells, Myeloid cells) and stromal cells (Fibroblasts, Endothelial cells), are observed in both 'normal' and 'tumor' conditions. Their mixed distribution in several UMAP clusters suggests the presence of an active tumor microenvironment (TME) PubMed search: tumor microenvironment colon cancer where immune and stromal cells interact with tumor cells. The distribution of these diploid cells across both normal and tumor areas highlights their potential roles in tumor progression or immune response.
  3. Comprehensive Cell Type Annotation: The hierarchical cell type annotations (major, minor, subset) are well-resolved across the UMAP, demonstrating the successful identification of diverse cell populations within the colon tissue. This detailed annotation forms a solid foundation for subsequent in-depth analyses, such as cell-cell interaction studies or differential gene expression.

Annotation Notes

The UMAP plots effectively visualize the underlying structure of the single-cell dataset and the quality of the cell type and ploidy annotations. The clear segregation of distinct cell populations, especially the highly specific clustering of aneuploid cells with tumor-derived epithelial cells, indicates a robust and biologically meaningful partitioning of the data. The presence of 'unassigned' cells is minimal and they do not form large, distinct clusters, suggesting good overall coverage and quality of the cell type annotations. The consistent clustering across multiple annotation levels (major, minor, subset) further supports the reliability of the cell type assignments.

2. Major Cell Type Score and Ploidy Visualization on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the distribution of major cell types based on calculated scores (HiCAT_major_score) and pre-assigned categorical labels (celltype_major). Additionally, the ploidy status (ploidy_dec) of individual cells is overlaid on the UMAP embedding. This allows for a comprehensive assessment of cell type annotation consistency, the overall structure of the single-cell dataset, and the spatial relationship between different cell populations and ploidy states.

Visual Summary

The UMAP embedding displays multiple distinct clusters of cells, reflecting the heterogeneity of the colon tissue.

Biological Interpretation

The strong concordance between the HiCAT_major_score visualizations and the celltype_major categorical labels on the UMAP provides high confidence in the accuracy and robustness of the major cell type annotations within this single-cell RNA-seq dataset. Each major cell type forms distinct, well-separated clusters, indicating successful dimensionality reduction and cell type identification.

Crucially, the ploidy_dec plot reveals a striking co-localization of aneuploid cells predominantly within the large cluster identified as "Intestinal Epithelial cell." Given the data context indicating 'Colon' tissue, 'tumor' condition, and the resolution of 'Intestinal Epithelial cell' as the tumor-origin cell type, this finding strongly supports the identification of malignant epithelial cells. Aneuploidy is a hallmark of cancer, and its specific enrichment within the presumed tumor cell population (Intestinal Epithelial cells) confirms their cancerous nature. The remaining cell types, largely immune and stromal components of the tumor microenvironment, are predominantly diploid, as expected for non-transformed cells supporting the tumor. The minor populations of aneuploid cells outside the main Intestinal Epithelial cell cluster might warrant further investigation but appear to be a small fraction.

Annotation Notes

The consistency between the calculated major cell type scores and the assigned categorical cell type labels on the UMAP is excellent, validating the quality of the cell type annotations. The clear separation of cell populations in the embedding further reinforces the distinct biological identities captured by the single-cell data. The successful identification and localization of aneuploid cells to the inferred tumor cell population (Intestinal Epithelial cells) is a key strength of this annotation and analysis. The very low scores for "Enteric neuron" suggest that while these cells may be present in the colon, they do not form a major distinct cluster at the same hierarchical level as other immune and stromal cells in this dataset, or they are exceedingly rare.

3. Marker Expression Dot Plot for Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of selected marker genes across various celltype_subset populations identified within the single-cell RNA-seq dataset from Colon tissue. The primary goal of this visualization is to validate the assigned cell type annotations by examining the specificity and expression levels of known or computationally derived marker genes. The plot displays genes identified as surfaceome markers that are highly expressed and enriched within each cell type group.

Visual Summary

The dot plot effectively visualizes marker gene expression, with celltype_subset groups on the y-axis and marker genes on the x-axis. Each dot's size represents the fraction of cells within a group expressing the gene, while its color intensity indicates the mean expression level of that gene in the respective group.

Key Cell Type Examples:

Immune Cell Subsets:

Biological Interpretation

The strong diagonal pattern in the dot plot indicates that the celltype_subset annotations are well-supported by distinct marker gene expression. The identified markers are generally consistent with established biological knowledge of these cell types in the human colon:

The surfaceome_only=True parameter in marker finding ensures that the identified markers are predominantly cell surface proteins, which are particularly valuable for cell identification, sorting, and potential therapeutic targeting.

Annotation Notes

Based on the marker expression dot plot, the celltype_subset annotations appear to be of high quality and resolution. The distinct and specific expression patterns for the vast majority of groups strongly support their assigned identities. The clear separation and consistent identification of both common and rare cell types using well-known marker genes indicate robust cell type clustering and annotation efforts. This robust annotation provides a strong foundation for subsequent analyses, especially in the context of Colon cancer where precise cell type identification is critical for understanding disease pathogenesis. No major discrepancies or highly ambiguous annotations are immediately apparent from this visualization.

4. Copy Number Variation (CNV) Analysis of Intestinal Epithelial Cells in Colon Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) in Intestinal Epithelial cells, which have been identified as the tumor-origin cell type within the provided single-cell RNA-seq dataset from colon tissue. The plot_cnv_heatmap tool was used to visualize log2(CNR) values across genomic spots, grouped by sample, and to summarize recurrently amplified chromosomal regions. The aim is to identify genomic instability characteristic of cancer and specific amplified loci that may drive tumor progression in these cells.

Visual Summary

CNV Heatmap

The heatmap displays log2(CNR) values for Intestinal Epithelial cells, ordered by genomic spot on the x-axis and grouped by cell_group on the y-axis. Red indicates genomic amplification (gain), and blue indicates genomic deletion (loss).

Significantly Amplified Regions Summary

The accompanying summary plots provide a quantitative overview of significantly amplified regions:

12q24.33:13q34 (75% frequency)

5q31.1:5q31.3 (50% frequency)

12q13.13:12q13.3 (50% frequency)

12q24.31:12q24.33 (50% frequency)

20p13:20q11.22 (50% frequency)

1q21.3:1q22 (50% frequency)

1q42.13:1q43 (38% frequency)

19p13.33:19q13.41 (38% frequency)

Biological Interpretation

The CNV analysis confirms widespread genomic instability in a subset of Intestinal Epithelial cells from tumor samples (T_cac groups), consistent with their role as the resolved tumor-origin cell type in colon cancer. The Diploid T_cac groups, despite originating from tumor samples, exhibit minimal CNVs, suggesting they may represent non-malignant epithelial cells within the tumor microenvironment or a diploid subpopulation that has not yet undergone extensive genomic alterations. The distinct CNV patterns between Diploid T_cac and T_cac populations highlight the genomic heterogeneity often observed within tumors.

Several amplified regions are of particular biological interest:

Amplification of 8q22.1:8q24.3 containing INTS8 and EIF3E

Clinical or Translational Implications

The identification of recurrent genomic amplifications, especially those involving known oncogenes like ERBB2, has significant clinical implications for colon cancer:

5. CNV-based UMAPs for Cell Type, Ploidy, Condition, and Sample Distribution

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) plots generated using copy number variation (CNV) patterns from single-cell RNA-seq data. The UMAPs visualize the cellular landscape colored by major cell type, minor cell type, ploidy status, experimental condition (normal vs. tumor), and individual sample. The primary goal is to assess the distribution and relationships of cell populations based on their underlying CNV profiles, particularly in the context of the inferred colon cancer.

Visual Summary

UMAP colored by celltype_major

The UMAP displays distinct clustering of major cell types based on their CNV profiles. Intestinal Epithelial cells (Ent.Epi) form a prominent, somewhat elongated cluster spanning the central and right-hand side of the embedding. T cells and B cells primarily occupy the left and upper-left regions, forming separate but adjacent clusters. Stromal cells and Myeloid cells also resolve into distinct, though somewhat more diffuse, areas within the embedding. Unassigned cells are broadly distributed.

UMAP colored by celltype_minor

At the minor cell type resolution, the overall structure largely aligns with the major cell types, demonstrating the robustness of the clustering. Intestinal Epithelial cells remain a cohesive group. T cell CD4+ and T cell CD8+ populations show clear separation while maintaining proximity. Similarly, distinct clusters are observed for B cells and Plasma cells. Macrophages and Dendritic cells, as minor myeloid subtypes, also exhibit their own specific distributions within the broader myeloid region.

UMAP colored by ploidy_dec

This UMAP reveals a striking and highly informative separation based on ploidy status. A distinct, dense cluster of Aneuploid cells (dark red) is clearly localized to the upper-right portion of the UMAP. The vast majority of cells are labeled Diploid (yellow) and occupy the remaining, more extensive regions of the embedding. A very small number of "Unclear" cells (purple) are scattered. This strong segregation indicates that CNV patterns are highly effective at distinguishing cells by their ploidy.

UMAP colored by condition

The UMAP colored by experimental condition shows a clear association with the ploidy status. Cells from the 'tumor' condition (dark purple) predominantly co-localize with the Aneuploid cluster in the upper-right region of the UMAP. Conversely, cells from the 'normal' condition (dark red) are mainly distributed across the regions dominated by Diploid cells. This strong correlation between 'tumor' condition and 'Aneuploid' status is a key observation.

UMAP colored by sample

The distribution across individual samples (B_cac4-15 and T_cac1-16) shows that both the diploid and aneuploid regions are populated by cells from multiple samples. While there is a general mixing, suggesting some shared underlying CNV patterns, some regional enrichments by specific samples are also visible. The distinct aneuploid cluster contains cells from various 'B_cac' and 'T_cac' samples, indicating shared malignant characteristics across different patients' tumor cells.

Biological Interpretation

The UMAPs provide critical insights into the cellular heterogeneity and the molecular basis of cell identity, particularly in the context of colon cancer.

Annotation Notes

The UMAP plots provide strong visual validation for the current cell type annotations, ploidy calls, and condition assignments. The clear distinction between aneuploid tumor cells and diploid non-malignant cells based purely on CNV features confirms the utility of CNV estimation for identifying tumor-derived cells. The consistency observed between major and minor cell type clustering further strengthens the confidence in the cell identity assignments.

6. Minor Cell Type Population Analysis Across Normal and Tumor Colon Samples

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different minor cell types within individual samples, grouped by physiological condition (normal vs. tumor). The plot was generated using the plot_celltype_population tool, with cell types classified at the 'minor' taxonomic level. This visualization provides an initial overview of cellular composition differences between healthy colon tissue and colon tumor tissue, offering insights into shifts in the tumor microenvironment.

Visual Summary

The bar plot displays the fractional composition of celltype_minor for each sample, normalized to 100%.

Biological Interpretation

The observed shifts in cell type populations strongly align with the inferred context of Colon cancer and the remodeling of the tumor microenvironment (TME).

  1. Tumor Cell Dominance and Variability: The Intestinal Epithelial cell is identified as the tumor-origin cell type. The high variability in its proportion in tumor samples can reflect several aspects:
    • In some samples, a high proportion might represent a high density of malignant epithelial cells.
    • In other samples, a reduced proportion could indicate extensive infiltration by stromal and immune cells, or a less epithelial-rich region of the tumor being sampled. The aneuploid status of 6.1% of cells in the dataset further supports the presence of malignant cells.
  2. Stromal Remodeling and Angiogenesis: The consistent increase in Fibroblast populations in tumor samples is a hallmark of cancer-associated fibroblasts (CAFs). CAFs play crucial roles in TME remodeling, promoting tumor growth, angiogenesis, and immune evasion [PubMed: 32327710]. Similarly, the increase in Endothelial cell populations is indicative of active angiogenesis, a process essential for tumor nutrient supply and growth [PubMed: 10660424].
  3. Immune Landscape in the TME: The changes in immune cell proportions suggest a complex immune response within the colon tumor microenvironment.
    • The general increase in Macrophage populations is consistent with the recruitment and differentiation of tumor-associated macrophages (TAMs). TAMs are often polarized towards pro-tumorigenic phenotypes (e.g., M2-like), contributing to immune suppression, angiogenesis, and metastasis [PubMed: 29773784].
    • The variable proportions of T cell CD4+ and T cell CD8+ highlight the heterogeneity of immune infiltration in colon cancer. Some tumors may be "immune-hot" with abundant T cell infiltration, while others are "immune-cold." CD8+ T cells are key anti-tumor effectors, but their function can be suppressed in the TME. CD4+ T cells encompass various subsets with pro- or anti-tumor roles [PubMed: 33262657].
    • The variable presence of B cell and Plasma cell populations also suggests diverse humoral immune responses, which can have complex roles in anti-tumor immunity or contribute to immune suppression [PubMed: 32296068].

Clinical or Translational Implications

The distinct cellular composition differences between normal and tumor colon samples, particularly the expansion of Fibroblast, Endothelial cell, and Macrophage populations, provide potential clinical insights:

  1. Biomarkers for Diagnosis/Prognosis: The relative abundance of certain cell types (e.g., high CAF or TAM density) could serve as prognostic markers for disease progression or recurrence in colon cancer patients.
  2. Therapeutic Targets: The increased prevalence of CAFs and endothelial cells points to the importance of the stromal compartment and angiogenesis in colon cancer progression. Therapies targeting CAFs or anti-angiogenic agents could be relevant therapeutic strategies. Similarly, targeting TAMs to reprogram them from pro-tumorigenic to anti-tumorigenic states is an active area of research.
  3. Immunotherapy Considerations: The variability in T cell infiltration underscores the heterogeneous immune landscape of colon tumors. This heterogeneity likely influences responsiveness to immunotherapies (e.g., checkpoint inhibitors). Stratifying patients based on their immune cell composition could help predict treatment response.

7. T Cell Subset Population Analysis in Normal and Colon Tumor Samples

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell and innate lymphoid cell (ILC) subsets within individual samples, comparing normal colon tissue to colon tumor tissue. The plot normalizes the cell subset counts to 100% within the major "T cell" population for each sample, providing a clear visual representation of compositional shifts between conditions. The goal is to identify differences in the immune cell landscape that may be associated with colon tumorigenesis.

Visual Summary

The stacked bar plots display the relative proportions of T cell and ILC subsets across individual normal (B_cac samples) and tumor (T_cac samples) samples.

Biological Interpretation

The observed shifts in T cell subset populations provide significant biological insights into the immune microenvironment in colon cancer.

Clinical or Translational Implications

The findings have several important clinical and translational implications for colon cancer:

---

References

  1. Treg function in cancer:

PubMed Search: "Tregs immune evasion cancer"

  1. Th17 cells in cancer:

PubMed Search: "Th17 cancer context dependent"

  1. Tregs as prognostic markers in CRC:

PubMed Search: "Tregs colorectal cancer prognosis"

  1. Treg targeting in cancer therapy:

PubMed Search: "Treg depletion cancer immunotherapy"

8. Differential Abundance of T cell and Immune Cell Subsets in Colon Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific T cell and other immune cell subsets between normal and tumor conditions within the colon tissue, derived from single-cell RNA-seq data. The box plots display the distribution of cell type proportions for each subset in normal versus tumor samples, with p-values indicating statistical significance of the observed differences. The analysis aimed to identify immune cell populations that are significantly altered in the context of colon cancer, with a focus on T cell subsets as per the user query, and a p-value cutoff of 0.1 for statistical significance.

Visual Summary

The box plots reveal statistically significant differences in the proportions of five immune cell subsets between normal and tumor conditions in the colon:

Biological Interpretation

The observed shifts in immune cell proportions provide insights into the immune microenvironment in colon cancer:

Increased Immunosuppression and Inflammation:

Compromised Anti-tumor Immunity:

Collectively, these findings suggest that the colon tumor microenvironment is characterized by an expansion of immune-suppressive and pro-inflammatory lymphocyte populations, coupled with a reduction in certain cells potentially involved in robust anti-tumor immunity or tissue homeostasis. This imbalance likely contributes to tumor survival and progression.

Clinical or Translational Implications

The distinct changes in immune cell subset proportions observed between normal and tumor colon tissue have several potential clinical and translational implications:

9. Macrophage Subset Population Analysis in Colon Normal and Tumor Tissues

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)) within individual samples, comparing normal colon tissue to tumor colon tissue. This type of analysis is crucial for understanding the immune microenvironment and its potential shifts during disease progression, particularly in the context of cancer where macrophage polarization plays a significant role.

Visual Summary

The plot displays two main panels, one for 'normal' samples and one for 'tumor' samples, each showing stacked bar plots representing the macrophage subset composition within different individual samples (identified by B_cac for normal and T_cac for tumor samples).

In normal samples:

In tumor samples:

Biological Interpretation

Macrophages are highly plastic immune cells that can differentiate into various functional phenotypes, broadly categorized as M1 (classically activated) and M2 (alternatively activated). M1 macrophages are generally pro-inflammatory and anti-tumorigenic, while M2 macrophages are typically associated with immune suppression, tissue repair, angiogenesis, and tumor promotion. The M2 category itself is heterogeneous, with subtypes like M2A, M2B, M2C, and M2D representing different polarization states.

The observed shifts in macrophage populations in colon tumor samples are highly significant:

Clinical or Translational Implications

The distinct shift in macrophage populations towards pro-tumorigenic M2 phenotypes in colon cancer tissues has several important clinical and translational implications:

10. Differential Abundance of Macrophage Subsets in Colon Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential proportions of specific macrophage subsets (Mac M2A, Mac M2B, and Mac M2D) between normal colon tissue and colon tumor samples. Box plots are used to visualize the distribution of cell type proportions for each subset across the two conditions, with statistical significance indicated by p-values. The objective is to identify macrophage populations whose abundance significantly shifts in the tumor microenvironment, providing insights into their potential roles in colon cancer.

Visual Summary

The box plots illustrate the celltype proportion of three macrophage subsets, Mac (M2A), Mac (M2B), and Mac (M2D), in normal and tumor conditions.

All three observed differences are statistically significant (p < 0.1), indicating a robust shift in the relative abundance of these macrophage subsets in colon cancer.

Biological Interpretation

Macrophages are highly plastic immune cells that polarize into different functional phenotypes, broadly categorized as M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor). The M2 phenotype itself is heterogeneous, with subtypes like M2A, M2B, M2C, and M2D exhibiting distinct roles.

The observed changes in macrophage subsets in colon tumor samples suggest a profound re-education of the macrophage compartment, consistent with the establishment of a pro-tumor microenvironment:

Collectively, these findings indicate a significant repopulation of the macrophage compartment in colon tumors, away from Mac (M2A) and markedly towards Mac (M2B) and Mac (M2D) phenotypes. This shift suggests an immune environment that likely fosters tumor growth, invasion, and immune evasion in the colon.

Clinical or Translational Implications

The differential abundance of macrophage subsets, particularly the enrichment of Mac (M2B) and Mac (M2D) in colon tumors, has important clinical and translational implications:

11. Ploidy Status of Intestinal Epithelial Cells in Normal and Tumor Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, Unclear) of Intestinal Epithelial cells across various samples from both normal and tumor conditions. The primary goal is to visualize and compare the proportion of cells with different ploidy states in a cell type identified as the likely origin of the tumor (Intestinal Epithelial cells), thereby assessing genomic stability in these populations.

Visual Summary

The stacked bar plots display the relative proportions of Aneuploid (maroon), Diploid (orange), and Unclear (light green) cells within Intestinal Epithelial cell populations for individual samples under 'normal' and 'tumor' conditions.

Biological Interpretation

The observed ploidy profiles provide strong evidence differentiating normal and tumor Intestinal Epithelial cells, aligning with established cancer biology principles.

Clinical or Translational Implications

The distinct ploidy patterns observed have important clinical and translational relevance, particularly for colon cancer:

12. Cell-Cell Interaction Landscape Alterations in Colon Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction patterns involving a comprehensive set of immune, stromal, and epithelial cell types in human colon tissue under normal and tumor conditions. The plot_cci_dots tool was utilized, displaying the top 80 most significant (based on p-value and mean expression) ligand-receptor interactions. This comparison aims to elucidate how cellular communication networks are altered in the context of colon cancer, focusing on interactions involving Intestinal Epithelial cells, Fibroblasts, Macrophages, T cells (CD4+, CD8+), B cells, Dendritic cells, Endothelial cells, ILCs, Mast cells, NK cells, Plasma cells, and Smooth muscle cells.

Visual Summary

CCI for normal

The visualization for normal colon tissue reveals a rich and diverse network of cell-cell interactions.

CCI for tumor

In stark contrast, the tumor condition presents a dramatically simplified cell-cell interaction landscape, showing only a very limited set of interactions among the top 80.

Comparative Summary

The most striking finding is the profound reduction in the diversity and number of significant cell-cell interactions in tumor tissue compared to normal tissue. The complex network observed in normal colon, encompassing epithelial, immune, and stromal cell types, is largely replaced by a highly restricted set of T cell-T cell interactions in the tumor microenvironment (TME). The complete absence of Intestinal Epithelial cell interactions (which would include the aneuploid tumor cells) in the top 80 interactions in tumor tissue is a critical observation.

Biological Interpretation

The observed shift in cell-cell interaction patterns from a diverse, multi-cellular network in normal colon to a highly restricted T cell-centric communication in colon tumors has significant biological implications:

Clinical or Translational Implications

The dramatic changes in cell-cell interaction patterns observed in colon cancer have critical implications for therapeutic development and patient management:

Therapeutic Target Prioritization:

13. Immune Checkpoint and Cell Cycle Pathway Cell-Cell Interactions in Colon Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCIs) involving a curated list of genes associated with immune checkpoint and cell cycle pathways in both normal and tumor colon tissue environments. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between specified minor cell types, aggregated by condition. The dot plot visualizes the statistical significance (-log10(p-value) represented by dot size) and the strength of interaction (log2(mean expression) represented by dot color) for detected cell-cell and gene-pair interactions. The analysis highlights key differences in immune-related signaling between normal and cancerous colon microenvironments.

Visual Summary

The analysis generated two dot plots comparing CCIs in "normal" and "tumor" conditions.

Normal Condition Plot:

Cell Type Pairs:

Tumor Condition Plot:

Biological Interpretation

The observed differences in cell-cell interactions between normal and tumor conditions provide crucial insights into immune dysregulation in colon cancer.

Loss of IFN-gamma Signaling in Tumor Microenvironment (TME):

Impaired T Cell Activation and Function via LCK/CD8 Receptor in TME:

Clinical or Translational Implications

These findings have significant clinical implications for understanding colon cancer progression and developing targeted immunotherapies.

Therapeutic Targets:

References:

  1. IFN-gamma in cancer immunity:

PubMed Search: "IFN-gamma cancer immunity"

  1. Immune evasion in colorectal cancer:

PubMed Search: "colorectal cancer immune evasion"

  1. LCK function in T cells:

UniProt: P06239 (LCK)

  1. T cell exhaustion:

PubMed Search: "T cell exhaustion cancer immunotherapy"

14. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns between major immune and stromal cells in human colon tissue, comparing 'normal' and 'tumor' conditions. The dot plot visualizes the strength (color intensity) and significance (dot size) of specific ligand-receptor interactions across individual samples from both conditions. The goal is to identify CCIs that are differentially regulated, providing insights into the immune microenvironment in colon cancer. The target cells for this analysis included T cells, B cells, Stromal cells, Endothelial cells, Myeloid cells, and Mast cells, with the plot specifically highlighting interactions within B and T cell subsets.

Visual Summary

The dot plot displays a clear differential pattern of cell-cell interactions between normal and tumor colon samples.

Biological Interpretation

The analysis reveals distinct shifts in key immune cell communication pathways when comparing normal colon tissue to tumor tissue. This aligns with the inferred context of Colon cancer and the presence of aneuploid cells.

Interactions Enriched in Normal Condition:

These interactions often point to homeostatic immune functions or effective immune surveillance.

  1. SEMA4D-CD72 (B cell | B cell)
    • Signaling Pathway/Mechanism: SEMA4D (Semaphorin 4D) on B cells interacts with CD72 on other B cells. This interaction is known to inhibit B cell activation and proliferation, playing a role in maintaining B cell homeostasis and preventing excessive humoral immune responses [1].
    • Potential as a Therapeutic Target: In contexts where B cell overactivity is detrimental (e.g., autoimmune diseases), modulating this pathway could be beneficial. However, in cancer, its reduced presence might suggest dysregulation of B cell control.
    • Relevant Therapeutic Agents: While direct therapeutic agents for this specific axis in cancer are not well-established, B-cell targeting therapies (e.g., anti-CD20) are used in lymphoma and autoimmune conditions.
  2. HLA-E - CD94:NKG2C / KLRRC2 (T CD8+ | T CD8+)
    • Signaling Pathway/Mechanism: HLA-E is a non-classical MHC class I molecule. CD94:NKG2C is an activating receptor on NK cells and certain T cells (including CD8+ T cells), while KLRRC2 (NKG2C) is a component of this receptor complex. Their interaction can modulate immune cell activation, particularly in response to stress or infection. In normal tissue, this might contribute to the fine-tuning of anti-viral or anti-tumor immune responses [2].
    • Potential as a Therapeutic Target: Activating NKG2C+ T cells or NK cells by modulating HLA-E could enhance anti-tumor immunity, especially in tumors that upregulate HLA-E to evade conventional T cell responses.
    • Relevant Therapeutic Agents: Therapeutic antibodies targeting HLA-E or NKG2C are under preclinical and early clinical investigation for cancer immunotherapy.
  3. ICAM1-related interactions (ICAM1_SPN, ICAM1_integrin_aLb2_complex, ICAM1_ITGAL) (T CD8+ | T CD8+)
    • Signaling Pathway/Mechanism: ICAM1 (CD54) is an intercellular adhesion molecule that binds to integrins like LFA-1 (composed of ITGAL/CD11a and ITGB2/CD18, forming the integrin_aLb2_complex) on T cells. SPN (CD43) also interacts with ICAM1. These interactions are fundamental for T cell adhesion, migration, and the formation of the immune synapse, critical for antigen recognition and T cell activation. Their robust presence in normal tissue indicates healthy immune cell trafficking and interaction [3].
    • Potential as a Therapeutic Target: Modulating T cell adhesion could impact immune cell infiltration into tissues. While beneficial in inflammation, reduced adhesion in tumor could impair anti-tumor T cell function.
    • Relevant Therapeutic Agents: Integrin inhibitors (e.g., Natalizumab targeting α4-integrin) are used in autoimmune diseases to prevent leukocyte trafficking. Efalizumab (an anti-CD11a antibody) was used for psoriasis but withdrawn.

Interactions Enriched in Tumor Condition:

These interactions are often associated with altered immune responses, immune evasion, or chronic inflammation within the tumor microenvironment.

  1. CD58-CD2 (T CD4+ | T CD4+ and T CD8+ | T CD8+)
    • Signaling Pathway/Mechanism: CD58 (LFA-3) is a co-stimulatory molecule that binds to CD2 on T cells. This interaction enhances T cell adhesion, activation, and cytokine production, playing an important role in immune synapse formation and T cell responses. Its increased prominence in tumor samples might suggest active T cell infiltration and interaction, potentially leading to T cell exhaustion in the context of chronic antigen exposure [4].
    • Potential as a Therapeutic Target: Modulating T cell activation.
    • Relevant Therapeutic Agents: Alefacept, an LFA-3/CD2 fusion protein, targets CD2 and is used in psoriasis to inhibit T cell activation.
  2. VSIR-HLA-F / VSIR-HLA-E (T CD8+ | T CD8+)
    • Signaling Pathway/Mechanism: VSIR (VISTA, B7-H5, PD-1H) is an immune checkpoint molecule that can suppress T cell function. HLA-F and HLA-E are non-classical MHC class I molecules. Interactions between VSIR and HLA-F/E, especially on T cells, could represent novel inhibitory pathways contributing to T cell dysfunction and immune evasion in the tumor microenvironment [5, 6].
    • Potential as a Therapeutic Target: Blocking the VSIR pathway could reinvigorate anti-tumor T cell responses, similar to PD-1/PD-L1 or CTLA-4 blockade.
    • Relevant Therapeutic Agents: Anti-VSIR monoclonal antibodies are in preclinical and early clinical development as novel cancer immunotherapies.
  3. SIRPG-CD47 (T CD4+ | T CD4+)
    • Signaling Pathway/Mechanism: CD47 is a "don't eat me" signal expressed on many cell types, binding to SIRPα (SIRPG) on myeloid cells to inhibit phagocytosis. While commonly studied in myeloid-tumor cell interactions, its presence between T CD4+ cells suggests a potential role in modulating T cell-T cell communication or T cell survival mechanisms within the TME [7].
    • Potential as a Therapeutic Target: Blocking CD47-SIRPα interaction is a promising strategy to promote anti-tumor immunity by enhancing phagocytosis of tumor cells and potentially modulating other immune cell interactions.
    • Relevant Therapeutic Agents: Anti-CD47 antibodies (e.g., Magrolimab) are in various stages of clinical trials for hematological and solid tumors.
  4. BTLA-TNFRSF14 (HVEM) (B cell | T CD4+)
    • Signaling Pathway/Mechanism: BTLA (B and T Lymphocyte Attenuator) is an inhibitory receptor on T cells that binds to TNFRSF14 (HVEM, Herpesvirus entry mediator) on B cells and other antigen-presenting cells. This interaction delivers inhibitory signals to T cells, contributing to T cell exhaustion and immune tolerance, which can be exploited by tumors to escape immune surveillance [8].
    • Potential as a Therapeutic Target: Blocking the BTLA-HVEM pathway could unleash anti-tumor T cell responses, making it another attractive target for cancer immunotherapy.
    • Relevant Therapeutic Agents: BTLA-blocking antibodies are currently in preclinical and early clinical investigations for various cancers.

Clinical or Translational Implications

The differential CCI patterns between normal and tumor colon tissue highlight the complex immune reprogramming occurring in colon cancer.

These findings underscore the importance of single-cell resolution analysis in dissecting the complex cellular crosstalk within the TME and guiding the development of more effective, personalized cancer immunotherapies.

---

References:

[1] CD72. GeneCards. (GeneCards)

[2] HLA-E. GeneCards. (GeneCards)

[3] ICAM1. GeneCards. (GeneCards)

[4] CD58. GeneCards. (GeneCards)

[5] VISTA (VSIR) as a novel immune checkpoint. PubMed search. (PubMed Search)

[6] HLA-F. GeneCards. (GeneCards)

[7] CD47-SIRPalpha signaling in cancer. PubMed search. (PubMed Search)

[8] BTLA-HVEM pathway in cancer. PubMed search. (PubMed Search)

15. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers differentially expressed in Intestinal Epithelial cells under 'normal' and 'tumor' conditions using single-cell RNA-seq data. The dot plot visualizes the mean expression and the fraction of cells expressing each marker across various sub-clusters of Intestinal Epithelial cells, categorized by their ploidy status and conditions. The goal was to pinpoint potential diagnostic, prognostic, or therapeutic targets, distinguishing between established and emerging candidates. The analysis focused on Intestinal Epithelial cells, which are identified as the tumor-origin cell type in this dataset.

Visual Summary

The dot plot, titled "Intestinal Epithelial cell condition-specific markers," effectively illustrates distinct expression profiles between Intestinal Epithelial cell sub-clusters associated with 'normal' and 'tumor' conditions.

The Y-axis displays various Intestinal Epithelial cell sub-clusters, broadly categorized into "Diploid T_cac" groups (upper section) and "T_cac" groups (lower section). This stratification likely reflects the ploidy status and/or distinct transcriptional states, with "Diploid T_cac" representing normal-like diploid cells and "T_cac" representing potentially aneuploid or tumor-associated cells, consistent with the observed aneuploidy in the dataset and the resolved tumor-origin cell type.

The X-axis lists a comprehensive set of surfaceome markers. The plot is divided into 'normal' and 'tumor' columns, representing the conditions under which marker expression was evaluated.

Key visual patterns:

Overall, the visualization clearly identifies distinct surfaceome expression signatures that differentiate normal Intestinal Epithelial cells from their tumor-associated counterparts, providing valuable candidates for further investigation as biomarkers and therapeutic targets in colorectal cancer.

Biological Interpretation

The distinct surfaceome marker profiles observed in normal versus tumor-associated Intestinal Epithelial cells provide crucial insights into the molecular changes occurring during colon cancer development and progression. The clear separation of "Diploid T_cac" groups (likely normal) from "T_cac" groups (likely tumor-derived) based on gene expression highlights the profound cellular reprogramming in malignancy.

Markers Prominent in Normal Intestinal Epithelial Cells

  1. MUC4 (Mucin 4, Cell Surface Associated)
    • Description: MUC4 is a large transmembrane mucin that contributes to the protective mucus layer of epithelial surfaces. It plays a role in maintaining epithelial barrier integrity and cellular signaling, often interacting with ErbB2 (HER2).
    • Associated Signaling Pathways & Mechanisms: In normal intestinal epithelia, MUC4 is involved in cell protection and can modulate cell growth and differentiation by influencing receptor tyrosine kinase signaling (e.g., EGFR/ErbB2 pathways) through indirect mechanisms. Its presence is crucial for maintaining the healthy mucosal barrier.
    • Relevance to Cancer: Downregulation or altered expression of MUC4 in colorectal cancer can indicate a loss of normal epithelial differentiation and barrier function, potentially contributing to tumor invasion and metastasis.
    • Relevant Therapeutic Agents: Not typically a direct therapeutic target for colon cancer due to its downregulation. However, its loss can serve as a prognostic marker.
    • Supporting Evidence: Its role in epithelial differentiation and barrier function in normal colon is well-established [Source: UniProt - P10307, GeneCards - MUC4].
    • Target Type: Less well-characterized marker with potential as a diagnostic/prognostic biomarker.

Markers Prominent in Tumor Intestinal Epithelial Cells

  1. CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5)
    • Description: A highly glycosylated cell surface protein involved in cell adhesion and signal transduction. CEACAM5 is a classic tumor-associated antigen, significantly overexpressed in various adenocarcinomas, including colorectal cancer.
    • Associated Signaling Pathways & Mechanisms: CEACAM5 promotes tumor cell proliferation, survival, invasion, and metastasis. It can influence cell cycle progression and apoptosis resistance. Its interactions can modulate signaling pathways involving receptor tyrosine kinases like EGFR.
    • Relevance to Cancer: Overexpression of CEACAM5 is a hallmark of many solid tumors and is associated with aggressive disease and poor prognosis. It contributes to immune evasion and chemotherapy resistance.
    • Relevant Therapeutic Agents: Established therapeutic target.
      • Tusamitamab ravtansine (ADC): An antibody-drug conjugate (ADC) specifically targeting CEACAM5, currently in clinical trials for CEACAM5-positive cancers. [PubMed Search: Tusamitamab ravtansine CEACAM5]
      • Labetuzumab govitecan (ADC): Another CEACAM5-targeting ADC investigated for metastatic colorectal cancer. [PubMed Search: Labetuzumab govitecan CEACAM5]
    • Supporting Evidence: Extensive literature documents CEACAM5 overexpression in colorectal cancer and its role in promoting tumor progression and as a target for ADCs [Source: GeneCards - CEACAM5].
    • Target Type: Established therapeutic target.
  2. CD44 (Cluster of Differentiation 44)
    • Description: A transmembrane glycoprotein and receptor for hyaluronic acid (HA), involved in cell adhesion, migration, and signaling. CD44 is a well-known marker for cancer stem cells (CSCs).
    • Associated Signaling Pathways & Mechanisms: CD44 plays critical roles in cell-cell and cell-matrix interactions, and its signaling is linked to cell proliferation, survival, and epithelial-mesenchymal transition (EMT). It can activate pathways such as PI3K/Akt, MAPK, and Wnt/β-catenin, contributing to tumor growth, metastasis, and drug resistance.
    • Relevance to Cancer: Its overexpression in tumor-associated Intestinal Epithelial cells is indicative of cancer stemness and increased metastatic potential.
    • Relevant Therapeutic Agents: Established therapeutic target / Biomarker.
      • Anti-CD44 antibodies: Several antibodies are under development to block CD44 function or deliver therapeutic payloads.
      • Targeting CD44v6: Specific isoforms like CD44v6 are being explored for CAR T-cell therapies in various cancers. [PubMed Search: CD44 cancer therapy]
    • Supporting Evidence: CD44's role as a cancer stem cell marker and its involvement in colorectal cancer progression and metastasis is widely recognized [Source: GeneCards - CD44].
    • Target Type: Established therapeutic target (especially for CSCs/metastasis) and important biomarker.
  3. CD47 (Cluster of Differentiation 47)
    • Description: A transmembrane glycoprotein that acts as a "don't eat me" signal, binding to SIRPα on phagocytic cells (e.g., macrophages) to inhibit their activity.
    • Associated Signaling Pathways & Mechanisms: Overexpression of CD47 in cancer cells allows them to evade immune surveillance by inhibiting phagocytosis. It is also involved in cell adhesion, migration, and apoptosis.
    • Relevance to Cancer: Its high expression in tumor-associated Intestinal Epithelial cells highlights a key mechanism of immune evasion employed by these cancer cells.
    • Relevant Therapeutic Agents: Established therapeutic target.
      • Anti-CD47 monoclonal antibodies: (e.g., Magrolimab, Letaplimab, Evorpacept). These antibodies block the CD47-SIRPα interaction, promoting macrophage-mediated phagocytosis of tumor cells. Currently in clinical trials for various solid and hematologic malignancies, including colorectal cancer. [PubMed Search: CD47 SIRPalpha cancer therapy]
    • Supporting Evidence: CD47 overexpression is a common feature across many human cancers, correlating with poor prognosis and immune evasion, with blocking antibodies showing promising anti-tumor activity [Source: UniProt - Q08722].
    • Target Type: Established therapeutic target.
  4. ITGB1 (Integrin Beta 1)
    • Description: A crucial subunit of various integrin heterodimers, cell surface receptors that mediate cell-extracellular matrix (ECM) interactions.
    • Associated Signaling Pathways & Mechanisms: Integrins are vital for cell adhesion, migration, proliferation, and survival. They transmit signals bidirectionally, linking the ECM to the cytoskeleton and activating intracellular pathways such as FAK, Src, PI3K/Akt, and MAPK, which are critical for tumor cell invasion, metastasis, and angiogenesis.
    • Relevance to Cancer: Overexpression and activation of ITGB1-containing integrins in tumor cells enhance their ability to migrate, invade surrounding tissues, and metastasize, and contribute to therapy resistance.
    • Relevant Therapeutic Agents: Potential therapeutic target.
      • Integrin inhibitors: While ITGB1 is a common subunit, targeting specific alpha subunits combined with beta1 (e.g., anti-α5β1 integrin antibodies) or pan-integrin approaches are under investigation to disrupt tumor-ECM interactions. [PubMed Search: ITGB1 cancer therapy]
    • Supporting Evidence: Overexpression and activation of ITGB1 integrins are frequently observed in various cancers, including colorectal cancer, and are associated with aggressive tumor behavior [Source: GeneCards - ITGB1].
    • Target Type: Less well-characterized but with strong potential as a therapeutic target.
  5. AREG (Amphiregulin)
    • Description: A ligand for the epidermal growth factor receptor (EGFR), acting as a growth factor.
    • Associated Signaling Pathways & Mechanisms: AREG binds to EGFR, leading to its activation and subsequent downstream signaling through pathways like MAPK (Ras-Raf-MEK-ERK) and PI3K/Akt. These pathways drive cell proliferation, survival, migration, and resistance to apoptosis. AREG often functions in an autocrine/paracrine manner to promote tumor growth.
    • Relevance to Cancer: High expression in tumor-associated Intestinal Epithelial cells suggests an active EGFR-driven proliferative and survival advantage, contributing to tumor progression and potentially resistance to anti-EGFR therapies.
    • Relevant Therapeutic Agents: Established therapeutic target (indirectly via EGFR).
      • EGFR inhibitors: Cetuximab and Panitumumab (monoclonal antibodies blocking EGFR) are approved for metastatic colorectal cancer. While they target the receptor, AREG's presence can influence response.
    • Supporting Evidence: AREG overexpression is a known prognostic marker in colorectal cancer and contributes to resistance to EGFR-targeted therapies [Source: UniProt - P15514].
    • Target Type: Established therapeutic target (as an EGFR ligand), also a potential biomarker for EGFR inhibitor response/resistance.
  6. LY6E (Lymphocyte Antigen 6 Family Member E)
    • Description: A glycosylphosphatidylinositol (GPI)-anchored protein whose precise molecular mechanisms are still being elucidated, but it is implicated in cell survival and proliferation.
    • Associated Signaling Pathways & Mechanisms: LY6E has been shown to promote cell survival, proliferation, and invasion in various cancers. It may modulate growth factor receptor signaling pathways, including EGFR, and impact cell adhesion.
    • Relevance to Cancer: Its robust expression in tumor-associated Intestinal Epithelial cells suggests a role in maintaining tumor cell viability and potentially contributing to tumor aggressiveness.
    • Relevant Therapeutic Agents: Potential therapeutic target.
      • Currently, no approved therapies directly target LY6E. However, its consistent overexpression in numerous cancers makes it an attractive candidate for developing novel therapies, such as antibody-drug conjugates (ADCs) or CAR T-cell therapies. [PubMed Search: LY6E cancer therapy]
    • Supporting Evidence: LY6E has been identified as an oncogene and a prognostic biomarker in several cancers, promoting tumor cell survival and metastasis [Source: GeneCards - LY6E].
    • Target Type: Less well-characterized marker with strong potential as a therapeutic target.

Clinical or Translational Implications

The identification of these cell-type and condition-specific surfaceome markers in Intestinal Epithelial cells holds significant clinical and translational potential for colon cancer.

  1. Diagnostic and Prognostic Biomarkers:
    • Markers like CEACAM5 and CD44, which are highly expressed in tumor-associated Intestinal Epithelial cells, can serve as valuable diagnostic markers, potentially detectable in tissue biopsies or liquid biopsies (e.g., circulating tumor cells). Their expression levels could also correlate with disease stage, aggressiveness, and patient prognosis.
    • The loss of MUC4 in tumor cells could be indicative of disease progression and loss of differentiation, potentially serving as an early indicator of malignant transformation or prognostic marker.
  2. Therapeutic Targets for Novel Drug Development:
    • Established Targets: The high expression of CEACAM5, CD44, and CD47 in tumor Intestinal Epithelial cells makes them compelling targets. Therapeutic strategies already exist or are in advanced clinical development, such as antibody-drug conjugates (ADCs) for CEACAM5 (Tusamitamab ravtansine, Labetuzumab govitecan) and anti-CD47 antibodies (Magrolimab, Letaplimab, Evorpacept) to overcome immune evasion. Targeting CD44 (especially specific isoforms) could be crucial for eradicating cancer stem cells and preventing metastasis.
    • Targeting AREG-EGFR axis: High AREG expression suggests that while EGFR inhibitors (Cetuximab, Panitumumab) are standard, the role of AREG in primary or acquired resistance to these therapies warrants further investigation.
    • Potential New Targets: ITGB1 and LY6E represent promising, less well-characterized therapeutic targets. Their consistent overexpression in tumor cells suggests they play critical roles in tumor biology. Further research into ITGB1 inhibitors or developing ADCs/CAR T-cells against LY6E could lead to new treatment options. Given their surface localization, these proteins are highly accessible for antibody-based therapies.
  3. Understanding Tumor Heterogeneity and Resistance:
    • The heterogeneity observed in marker expression across different "T_cac" sub-clusters underscores the complexity of colon tumors. Understanding these variations could lead to personalized treatment strategies, where specific therapies are matched to the marker profile of an individual patient's tumor.
    • Identifying these surface markers can help elucidate mechanisms of drug resistance and inform strategies to overcome them, for example, by combining therapies that target different pathways or cell populations.

In conclusion, this analysis provides a strong foundation for developing targeted therapies and diagnostic tools tailored to the specific molecular landscape of Intestinal Epithelial cell-derived colon cancer.

16. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed by Fibroblast subclusters in normal and tumor colon tissue using a dot plot. The goal is to characterize the distinct surface protein profiles of fibroblasts in different conditions, particularly focusing on potential therapeutic targets in the context of colon cancer. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for each gene across various fibroblast subclusters, grouped by 'normal' and 'tumor' conditions.

Visual Summary

The dot plot clearly differentiates the surfaceome profiles of Fibroblast subclusters between normal and tumor conditions.

Biological Interpretation

The observed shift in surfaceome markers highlights the phenotypic transformation of normal fibroblasts into CAFs within the colon tumor microenvironment. This transformation is crucial for tumor progression and offers potential therapeutic avenues.

Markers in Normal Fibroblasts

While the primary focus is on tumor-associated markers, several genes are prominently expressed in normal fibroblast subclusters, potentially representing quiescent or tissue-maintenance functions.

EMP2 (Epithelial Membrane Protein 2)

PROCR (Protein C Receptor, Endothelial)

CD74 (HLA Class II Histocompatibility Antigen Gamma Chain)

Markers in Tumor-Associated Fibroblasts

The high and prevalent expression of specific surface markers in tumor fibroblasts points to their active involvement in tumor progression and identifies them as key components of the tumor microenvironment (TME) in colon cancer.

THY1 (CD90)

PDGFRB (Platelet-Derived Growth Factor Receptor Beta)

MMP14 (Matrix Metallopeptidase 14)

ITGAV (Integrin Alpha V)

EDNRA (Endothelin Receptor Type A)

JAG1 (Jagged Canonical Notch Ligand 1)

ICAM1 (Intercellular Adhesion Molecule 1)

Clinical or Translational Implications

The distinct surfaceome profiles of tumor-associated fibroblasts identified in this analysis have significant clinical and translational implications for colon cancer:

Overall, this analysis provides a valuable resource for understanding CAF heterogeneity in colon cancer and highlights several compelling surfaceome-expressed candidates for further investigation as diagnostic markers and therapeutic targets.

17. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers within the T cell CD4+ population from single-cell RNA-seq data derived from human colon tissue, comparing 'normal' and 'tumor' conditions. The dot plot visualizes the expression of 26 selected surfaceome genes across different T cell CD4+ subclusters. Circle size represents the fraction of cells expressing the marker, while color intensity indicates the mean expression level within each cluster. The primary goal is to identify markers that distinguish CD4+ T cell states and functions in the tumor microenvironment (TME) versus normal tissue.

Visual Summary

The dot plot clearly segregates T cell CD4+ subclusters and their marker expression patterns based on the 'normal' and 'tumor' conditions.

The differential expression patterns highlight distinct phenotypic and functional states of T cell CD4+ populations in response to the tumor microenvironment.

Biological Interpretation

The observed differential expression of surfaceome markers in T cell CD4+ subsets between normal and tumor conditions suggests significant shifts in T cell function, trafficking, and interaction within the colon cancer microenvironment. The inferred disease context is Colon cancer, with Intestinal Epithelial cells identified as the tumor-origin cell type, and a significant aneuploid population observed. CD4+ T cells play a crucial role in orchestrating immune responses, and their phenotype can dictate the outcome of anti-tumor immunity or immune evasion.

Here is an interpretation of the identified surfaceome markers:

Markers Predominantly Expressed in Normal CD4+ T cell Clusters

These markers are generally indicative of a homeostatic, naive, or central memory phenotype, or T cells involved in normal tissue function and immune surveillance.

SLC2A3 (GLUT3)

CCR7

CD55 (DAF)

AREG (Amphiregulin)

PTGER4 (EP4)

IL6ST (GP130)

Markers Predominantly Expressed in Tumor CD4+ T cell Clusters

These markers are often associated with T cell activation, differentiation, exhaustion, or specific TME adaptation, indicative of their interaction with tumor cells and other stromal cells.

EMP3 (Epithelial Membrane Protein 3)

FLT3LG (Fms-like Tyrosine Kinase 3 Ligand)

BSG (CD147, Basigin)

SELPLG (CD162, PSGL-1)

CCR6

SIRPG (Signal Regulatory Protein Gamma)

RNF167 (Ring Finger Protein 167)

BST2 (CD317, PDCA-1)

LMAN2 (Lectin, Mannose-Binding 2)

EMB (Embigin)

CD82 (KAI1)

TNFRSF1B (TNFR2)

SIT1 (SHP2-Interacting Transmembrane Adaptor Protein 1)

CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

LDLRAD4 (Low-Density Lipoprotein Receptor-Related Protein 4)

SLAMF1 (CD150, SLAM)

TNFRSF4 (OX40)

TIGIT (T cell Immunoreceptor with Ig and ITIM domains)

Markers Ubiquitously Expressed Across CD4+ T cell Clusters

These are fundamental markers for identifying and classifying T cells.

CD3

CD4

Clinical or Translational Implications

The distinct surfaceome profiles of CD4+ T cells in normal versus tumor colon tissue have significant clinical and translational implications for colon cancer:

  1. Biomarker Identification: The identified tumor-enriched markers (e.g., CTLA4, TIGIT, TNFRSF4, TNFRSF1B, BSG, CCR6) serve as potential biomarkers to distinguish tumor-infiltrating CD4+ T cells (TILs) from T cells in healthy tissue. These markers could be used for patient stratification, predicting response to immunotherapy, or monitoring disease progression.
  2. Therapeutic Targets for Immunotherapy:
    • Immune Checkpoint Blockade: The strong upregulation of inhibitory receptors like CTLA4 and TIGIT on tumor-associated CD4+ T cells highlights their critical role in immune suppression within the colon TME. These findings strongly support the rationale for utilizing anti-CTLA4 (e.g., ipilimumab) and anti-TIGIT antibodies (e.g., tiragolumab) to reactivate exhausted T cells and unleash anti-tumor immunity in colon cancer patients. Combinatorial approaches with other checkpoint inhibitors (e.g., anti-PD-1/PD-L1) may be particularly effective.
    • Co-stimulatory Agonists: The concomitant expression of co-stimulatory receptors like TNFRSF4 (OX40) suggests that a subset of these T cells might be amenable to activation strategies. Agonistic anti-OX40 antibodies could be employed to enhance T cell survival, proliferation, and effector functions, tipping the balance towards anti-tumor immunity.
    • Modulating Treg Activity: The upregulation of TNFRSF1B (TNFR2), which is crucial for Treg survival and suppressive function, indicates a potential strategy to reduce the immunosuppressive burden in the TME by blocking TNFR2 signaling. Similarly, blocking CCR6 could alter the recruitment of immunosuppressive Tregs.
    • Targeting TME Interactions: Markers like BSG (CD147) and SELPLG suggest T cell interactions with the tumor microenvironment. While not direct T cell targets for activation, understanding these interactions could inform strategies to remodel the TME or enhance T cell infiltration.
  3. Understanding T Cell Plasticity and Exhaustion: The shift from a largely CCR7+ (naive/central memory) phenotype in normal tissue to T cells expressing multiple activation/exhaustion markers (CTLA4, TIGIT, OX40, TNFR2) in tumors reflects the adaptation and functional changes of CD4+ T cells in the hostile colon cancer microenvironment. This highlights the complex interplay of activation and suppression that dictates the overall anti-tumor immune response. Further characterization of these CD4+ subsets (e.g., Th1, Th17, Treg, exhausted) could refine therapeutic strategies.
  4. Drug Development: These identified surfaceome markers provide a rich resource for developing novel immunotherapies, including antibody-drug conjugates, CAR-T cell targets, or bispecific antibodies that specifically engage or deplete distinct T cell CD4+ subsets based on their expression profile in the tumor.

Overall, this analysis provides a clear molecular signature of CD4+ T cells in the colon cancer microenvironment, offering valuable insights for the development of targeted immunotherapeutic strategies.

18. Differential Expression of Cell Cycle Genes in Intestinal Epithelial Cells in Colon Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential expression of a curated set of cell cycle pathway genes in Intestinal Epithelial cells, comparing 'normal' and 'tumor' conditions. The plot_box_for_gene_expression_with_signif_difference tool was used to identify and visualize genes with statistically significant expression differences. A total of 24 genes, chosen from the specified cell cycle pathway list based on their significant differential expression (p-value < 0.05), are displayed. The visualization presents box plots showing the "Expressing cell fraction (sample)" for each gene across normal and tumor samples.

Visual Summary

The visualization displays box plots for 24 distinct cell cycle-related genes, comparing their expression in Intestinal Epithelial cells from 'normal' versus 'tumor' samples.

Biological Interpretation

The observed widespread and significant upregulation of numerous cell cycle genes in Intestinal Epithelial cells within tumor samples strongly supports the inferred diagnosis of Colon cancer. Cancer is fundamentally characterized by uncontrolled cell proliferation, which relies on the dysregulation and hyperactivation of the cell cycle machinery.

The coordinated upregulation of these diverse cell cycle-related genes in the tumor-origin Intestinal Epithelial cells provides strong evidence for enhanced and dysregulated proliferative processes characteristic of colon cancer.

Clinical or Translational Implications

The comprehensive upregulation of cell cycle pathway genes in tumor-derived Intestinal Epithelial cells has several clinical and translational implications:

This analysis highlights the profound alteration of the cell cycle machinery in colon cancer and identifies multiple avenues for potential clinical exploitation.

References

  1. Cyclins and CDKs: PubMed search for "cyclin cdk cell cycle cancer"
  2. APC/C, Chromosome Segregation: PubMed search for "ANAPC BUB RAD21 SMC1A chromosome segregation cancer"
  3. DNA Damage Response (PRKDC, SFN): GeneCards: SFN, GeneCards: PRKDC
  4. MYC Oncogene: GeneCards: MYC
  5. HDACs: GeneCards: HDAC1, GeneCards: HDAC2
  6. 14-3-3 Proteins (YWHA family): PubMed search for "14-3-3 protein cell cycle cancer"
  7. GSK3B and Wnt Signaling: GeneCards: GSK3B
  8. CDK4/6 Inhibitors in Cancer: PubMed search for "CDK4/6 inhibitors cancer"
  9. HDAC Inhibitors in Cancer: PubMed search for "HDAC inhibitors cancer"

19. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results (GSA) for "Intestinal Epithelial cell" populations under different conditions or states, specifically comparing:

  1. Diploid Intestinal Epithelial cells against all other diploid cell types.
  2. Intestinal Epithelial cells from 'normal' tissue against all other cell types from 'normal' tissue.
  3. Intestinal Epithelial cells from 'tumor' tissue against all other cell types from 'tumor' tissue.

The results highlight biological processes and pathways that are significantly upregulated in Intestinal Epithelial cells within each specified context, providing insight into their intrinsic functional characteristics. The terms are ranked by the negative logarithm of the p-value (-log(p-val)), indicating the statistical significance of their enrichment.

Visual Summary

The provided bar plots illustrate the top enriched GO terms for Intestinal Epithelial cells in three distinct comparisons, ordered by their statistical significance (-log(p-val)). Each plot includes a second panel displaying -log(q-val) (FDR-adjusted p-value), though its scale and interpretation require careful consideration.

Diploid Intestinal Epithelial Cells vs. Other Diploid Cells

This plot shows GO terms enriched in Intestinal Epithelial cells with a diploid ploidy status, relative to other diploid cell types.

Normal Intestinal Epithelial Cells vs. Other Normal Cells

This plot shows GO terms enriched in Intestinal Epithelial cells from normal colon tissue, relative to other cell types within the normal tissue context.

Tumor Intestinal Epithelial Cells vs. Other Tumor Cells

This plot reveals GO terms significantly enriched in Intestinal Epithelial cells originating from tumor tissue, relative to other cell types within the tumor microenvironment.

Biological Interpretation

The analysis reveals distinct functional profiles for Intestinal Epithelial cells (IECs) across different cellular states (diploid, normal, tumor), consistent with their central role in colon health and disease.

Intrinsic Functions of Diploid/Normal Intestinal Epithelial Cells

In both diploid and normal conditions, IECs exhibit enrichment for pathways associated with their fundamental physiological roles:

Hallmarks of Tumor Intestinal Epithelial Cells

The functional profile of Intestinal Epithelial cells dramatically shifts in the tumor context, showcasing characteristic hallmarks of cancer:

Clinical or Translational Implications

The profound differences in GO enrichment between normal and tumor Intestinal Epithelial cells offer several clinical and translational insights for colon cancer:

20. Gene Set Enrichment Analysis of Colon Cancer Cell Types

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results across various cell types identified in single-cell RNA-seq data from human Colon tissue, comparing 'normal' and 'tumor' conditions. The plot displays the Normalized Enrichment Score (NES) and significance (-log(p-val)) for 120 selected gene sets, providing insights into differentially active biological pathways in specific cell populations within the colon cancer microenvironment. The comparisons are primarily focused on condition-specific enrichment for each cell type (e.g., 'B cell in normal condition vs. B cell in tumor condition', or vice-versa). For Intestinal Epithelial cells, additional comparisons by ploidy status (Diploid, Aneuploid) within the tumor context are included.

Visual Summary

The provided dot plot visualizes GSEA results:

The plot highlights a complex interplay of pathway activation and repression across different cell types and conditions, with distinct patterns emerging in tumor-associated cells compared to their normal counterparts.

Biological Interpretation

General Cancer Hallmarks and Metabolic Reprogramming

Many classic cancer-associated pathways are consistently enriched in tumor-associated cells:

Immune Microenvironment Dysregulation

The GSEA results reveal significant alterations in immune cell functions within the tumor microenvironment:

Fibroblast Activation in Tumor Stroma

Tumor-associated Fibroblasts exhibit a distinct activation profile:

Ploidy-Specific Differences in Tumor Intestinal Epithelial Cells

Comparing diploid and aneuploid Intestinal Epithelial cells within the tumor context provides nuanced insights:

Clinical or Translational Implications

The GSEA results provide several potential clinical and translational avenues for colon cancer:

21. Discussion

The single-cell RNA sequencing analysis of human colon tissue provides a multi-faceted view of colon cancer, integrating transcriptomic profiling, copy number variations (CNVs), and cell-cell interaction dynamics. A primary finding, reinforced by UMAP visualizations and ploidy analysis (Sections 1, 2, 5, 11), is the unambiguous identification of Intestinal Epithelial cells (IECs) as the tumor-origin cell type. These cells in tumor samples exhibit striking aneuploidy, a hallmark of malignancy, and harbor recurrent genomic amplifications (Section 4), notably including ERBB2 on 17q12:17q21.2 and regions on 8q22.1:8q24.3 (containing INTS8 and EIF3E). This genomic instability underpins the profound phenotypic changes observed in tumor IECs.

The tumor microenvironment (TME) undergoes extensive remodeling, crucial for cancer progression. Immune cell population analysis reveals significant shifts (Sections 6, 7, 8, 9, 10). Specifically, a substantial increase in regulatory T cells (Tregs), Th17, and Th22 populations in tumor tissue points towards an immunosuppressive and pro-inflammatory milieu. Concurrently, macrophage populations polarize towards pro-tumorigenic M2B and M2D phenotypes, actively contributing to immune evasion and tumor growth. Cancer-associated fibroblasts (CAFs) also emerge as a prominent component of the tumor stroma, characterized by specific surface markers (Section 16) like THY1, PDGFRB, and MMP14, indicative of their activated state and role in extracellular matrix remodeling and angiogenesis.

Cell-cell interaction (CCI) analysis highlights a dramatic disruption of communication networks in the TME (Sections 12, 13, 14). While normal colon tissue exhibits a rich, diverse network of epithelial-immune and immune-immune interactions (e.g., strong IFN-gamma signaling and T cell activation pathways), the tumor microenvironment presents a significantly simplified landscape. Key findings include the loss of crucial IFN-gamma signaling among T cells and a marked impairment of T cell activation pathways (LCK/CD8 receptor interactions). Conversely, tumor-specific interactions emerge, involving novel immune checkpoints like VSIR-HLA-F/E, BTLA-HVEM, and SIRPG-CD47, which actively contribute to T cell dysfunction and immune evasion. The general absence of epithelial-immune interactions within the most prominent tumor CCIs further underscores the immune-excluded or suppressed nature of the malignant epithelial cells.

Functionally, tumor-derived IECs display hallmarks of aggressive malignancy. Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) (Sections 19, 20) reveal overwhelming enrichment for pathways related to hyper-proliferation (e.g., ribosome biogenesis, protein processing, DNA replication, cell cycle) and altered metabolism (e.g., glycolysis, oxidative phosphorylation). This is corroborated by the widespread and statistically significant upregulation of numerous cell cycle pathway genes, including CCND1, MYC, CDK4/6, and HDACs, in tumor IECs (Section 18). Concurrently, tumor suppressor pathways like p53 signaling are depleted. These analyses underscore the intrinsic drive of tumor cells for uncontrolled growth and adaptation.

Finally, the identification of condition-specific surfaceome markers (Sections 15, 16, 17) in tumor IECs, CAFs, and CD4+ T cells provides a critical foundation for therapeutic development. Established targets such as CEACAM5, CD44, and CD47 on tumor cells, and immune checkpoints like CTLA4 and TIGIT on T cells, show high expression. Promising novel targets on CAFs (e.g., PDGFRB, MMP14) and potentially exhausted T cells (e.g., TNFRSF1B, OX40) highlight avenues for stromal and immune modulation. Overall, this comprehensive analysis provides an integrated understanding of the genomic and transcriptomic changes in human colon cancer, detailing the complex interplay between tumor cells and their microenvironment, and offering a robust platform for the identification and validation of next-generation diagnostic and therapeutic strategies.

Hypotheses:

  1. The observed increase in immunosuppressive cell populations (Tregs, M2 macrophages) and the activation of specific immune checkpoint interactions (VSIR-HLA-F/E, BTLA-HVEM, SIRPG-CD47, CTLA4, TIGIT) in the tumor microenvironment directly correlate with the functional suppression of anti-tumor T cell responses (e.g., reduced IFN-gamma signaling and LCK/CD8 receptor interactions) and promote immune evasion in colon cancer.
  2. The widespread genomic instability and aneuploidy in Intestinal Epithelial cells, along with specific recurrent gene amplifications (e.g., ERBB2, INTS8, EIF3E), drive a hyper-proliferative state and profound metabolic reprogramming, characterized by enhanced glycolysis and oxidative phosphorylation, thereby supporting aggressive tumor growth and contributing to altered protein homeostasis.
  3. The unique activation and distinct surfaceome profile of Cancer-Associated Fibroblasts (CAFs), including upregulation of PDGFRB, ITGAV, MMP14, EDNRA, and JAG1, remodel the extracellular matrix and foster an immunosuppressive milieu, which collectively facilitates tumor invasion, angiogenesis, and metastasis in colon cancer.
  4. The drastic reduction in the diversity and number of significant cell-cell interactions, particularly the loss of epithelial-immune crosstalk and the prominence of T cell-T cell inhibitory interactions, in tumor tissue indicates a fundamental rewiring or suppression of intercellular communication, leading to an 'immune desert' phenotype or active immune exclusion mechanisms.
  5. The high and specific expression of novel surface markers (e.g., LY6E, TNFRSF1B, OX40) on distinct cell populations within the tumor microenvironment represents unexplored therapeutic vulnerabilities beyond established targets, offering potential for precision medicine approaches to modulate tumor growth, stromal support, or immune responses.

Potential therapeutic targets:

  1. CEACAM5: A classic tumor-associated surface antigen significantly overexpressed in tumor-origin Intestinal Epithelial cells, promoting tumor cell proliferation, survival, invasion, and immune evasion. Evidence: Section 15: "CEACAM5 is a classic tumor-associated antigen, significantly overexpressed in various adenocarcinomas, including colorectal cancer. It promotes tumor cell proliferation, survival, invasion, and metastasis. It can influence cell cycle progression and apoptosis resistance. Its high expression in tumor-associated Intestinal Epithelial cells highlights a key mechanism of immune evasion." Listed as an 'Established therapeutic target'. Validation: Test the efficacy of CEACAM5-targeting antibody-drug conjugates (ADCs) like Tusamitamab ravtansine or Labetuzumab govitecan in colon cancer cell lines, patient-derived organoids, and xenograft models to assess tumor growth inhibition and patient response.
  2. CD47: Upregulated surface protein on tumor-origin Intestinal Epithelial cells that acts as a 'don't eat me' signal, binding to SIRPα on phagocytic cells to inhibit their activity, thereby enabling immune evasion. Evidence: Section 15: "Overexpression of CD47 in cancer cells allows them to evade immune surveillance by inhibiting phagocytosis. Its high expression in tumor-associated Intestinal Epithelial cells highlights a key mechanism of immune evasion employed by these cancer cells." Listed as an 'Established therapeutic target'. Validation: Evaluate anti-CD47 monoclonal antibodies (e.g., Magrolimab, Letaplimab) in preclinical colon cancer models to demonstrate enhanced macrophage-mediated phagocytosis of tumor cells, potentially in combination with chemotherapy or other immunotherapies.
  3. ERBB2 (HER2): The ERBB2 gene is recurrently amplified (50% frequency) in tumor-associated Intestinal Epithelial cells, suggesting it is a significant driver oncogene in these colon cancer samples. Evidence: Section 4: "Amplification of 17q12:17q21.2 containing ERBB2 is a well-established oncogene whose amplification and overexpression drive tumor growth in various cancers, including a subset of colorectal cancers. Its high frequency (50%) in the T_cac cells suggests it could be a significant driver in these colon cancer samples." Validation: Assess the efficacy of HER2-targeted therapies (e.g., trastuzumab, pertuzumab, or antibody-drug conjugates like fam-trastuzumab deruxtecan) in colon cancer patient-derived xenograft (PDX) models or organoids with confirmed ERBB2 amplification, to confirm therapeutic response.
  4. PDGFRB: A prominent receptor tyrosine kinase highly expressed on activated Cancer-Associated Fibroblasts (CAFs), driving fibroblast proliferation, differentiation, extracellular matrix deposition, and angiogenesis, all critical for tumor progression. Evidence: Section 16: "PDGFRB is a prominent marker of activated CAFs. Its signaling drives fibroblast proliferation, differentiation, and the extensive deposition of extracellular matrix (ECM) components, contributing to tumor desmoplasia. It also plays a role in pericyte recruitment and angiogenesis." Listed as an 'Established therapeutic target'. Validation: Test multi-kinase inhibitors with anti-PDGFR activity (e.g., imatinib, sunitinib) in preclinical models to determine their impact on CAF activation, TME stiffness, tumor growth, and metastatic potential.
  5. MMP14: A membrane-anchored matrix metalloproteinase highly expressed by CAFs, crucial for remodeling the ECM, facilitating tumor cell invasion, and contributing to angiogenesis. Evidence: Section 16: "MMP14 is highly expressed by CAFs and is crucial for remodeling the ECM, thereby facilitating tumor cell invasion, intravasation, and metastasis. It also contributes to angiogenesis and immune cell infiltration within the TME." Listed as a 'Potential therapeutic target'. Validation: Evaluate selective MMP14 inhibitors in organoid or xenograft models to demonstrate reduced tumor invasion and metastasis. Investigate if MMP14 inhibition improves delivery and efficacy of co-administered chemotherapies or immunotherapies due to TME normalization.
  6. CTLA4: A crucial inhibitory immune checkpoint receptor strongly upregulated on tumor-associated CD4+ T cells, dampening T cell activation and contributing significantly to immune suppression and evasion in the TME. Evidence: Section 17: "CTLA4 is a crucial negative regulator of T cell activation, often upregulated on activated T cells and regulatory T cells (Tregs) in the TME. Its high expression on tumor-associated CD4+ T cells is a strong indicator of immune suppression, T cell exhaustion, or the presence of immunosuppressive Tregs, contributing significantly to tumor immune evasion." Listed as an 'Established therapeutic target'. Validation: Utilize anti-CTLA4 monoclonal antibodies (e.g., Ipilimumab) in clinical trials for colon cancer, particularly in combination with other immunotherapies (e.g., anti-PD-1/PD-L1), to enhance T cell activation and anti-tumor immunity.
  7. TIGIT: An emerging inhibitory immune checkpoint receptor highly expressed on tumor-associated CD4+ T cells, co-expressed with other inhibitory receptors, and implicated in suppressing T cell activation and proliferation, thereby contributing to immune evasion. Evidence: Section 17: "TIGIT is a relatively new but significant immune checkpoint, often co-expressed with other inhibitory receptors like PD-1 on exhausted T cells and Tregs in the TME. Its high expression indicates a suppressive phenotype contributing to immune evasion in colon cancer." Listed as an 'Emerging immune checkpoint blockade target'. Validation: Conduct preclinical and clinical evaluations of TIGIT-blocking antibodies (e.g., Tiragolumab) alone and in combination with anti-PD-1 therapy to demonstrate restored T cell function and enhanced anti-tumor responses in colon cancer.
  8. TNFRSF1B (TNFR2): Highly expressed on regulatory T cells (Tregs) and activated effector T cells in the TME, it promotes Treg survival, proliferation, and suppressive function, contributing significantly to immune tolerance and evasion. Evidence: Section 17: "TNFR2 is highly expressed on regulatory T cells (Tregs) and often on activated effector T cells. In the TME, it plays a critical role in the survival, proliferation, and suppressive function of Tregs, contributing significantly to immune tolerance and evasion. Its expression on tumor-associated CD4+ T cells points towards a more suppressive or anergic phenotype." Listed as an 'Emerging immune checkpoint target'. Validation: Evaluate anti-TNFR2 antibodies in preclinical models to assess their ability to deplete or inhibit Treg function and consequently enhance anti-tumor T cell responses, potentially in combination with other immunotherapies.

Follow-up validation ideas:

  1. Flow Cytometry/Immunohistochemistry: Validate population shifts of immune and stromal cells (e.g., Treg, Th17, M2 macrophage subsets, CAFs) and protein-level expression of key surface markers (e.g., CEACAM5, CD47 on IECs; THY1, PDGFRB on Fibroblasts; CTLA4, TIGIT, OX40, TNFR2 on T cells) in independent human colon cancer cohorts and adjacent normal tissues.
  2. Spatial Transcriptomics/Proteomics: Map the precise localization of distinct immune and stromal cell subsets, as well as specific ligand-receptor interactions (e.g., VSIR-HLA-F/E, BTLA-HVEM), within the colon tumor architecture to understand their spatial relationships, interactions, and contributions to immune exclusion or suppression in situ.
  3. In vitro/Ex vivo Functional Assays: Conduct co-culture experiments with isolated tumor IECs, CAFs, and immune cells to investigate the functional impact of identified interactions and pathways on cell proliferation, migration, invasion, immune evasion, and T cell activation/exhaustion. For example, test inhibitors of PDGFRB or MMP14 on CAF-mediated ECM remodeling and tumor cell invasion.
  4. CRISPR/shRNA Knockdown/Overexpression: Genetically manipulate identified target genes (e.g., CEACAM5, LY6E in tumor cells; PDGFRB, MMP14 in CAFs; TIGIT, CTLA4 in T cells) in relevant colon cancer cell lines or patient-derived organoids to assess their functional impact on tumor cell fitness, TME interactions, and immune responses.
  5. Patient-Derived Xenograft (PDX) Models / Syngeneic Mouse Models: Evaluate the in vivo efficacy of therapeutic agents targeting identified pathways and surface markers (e.g., anti-CEACAM5 ADCs, anti-CD47 antibodies, PDGFRB inhibitors, anti-TIGIT/CTLA4 antibodies) alone or in combination, monitoring tumor growth, metastasis, and immune cell infiltration/function.
  6. FISH/qPCR for CNVs: Validate recurrent CNV amplifications (e.g., ERBB2, INTS8, EIF3E) identified in tumor IECs at the genomic DNA level using Fluorescence In Situ Hybridization (FISH) on tissue sections, and assess their gene expression changes via targeted qPCR or single-molecule FISH in specific cell populations.

Limitations:

This report's findings are based on computational analysis of single-cell RNA sequencing data and inferred copy number variations, thus providing associations rather than direct causality. While the cell type annotations and ploidy calls are robust, the interpretation of some statistical measures (e.g., GSA q-values) had ambiguous visual scaling and requires cautious interpretation. Cell-cell interaction predictions are based on gene expression and known ligand-receptor pairs, not direct biochemical validation. The observed tumor heterogeneity between samples implies that specific findings may not universally apply to all colon cancer cases. Furthermore, the specific histological subtype and stage of colon cancer are not determined from the provided data. Therefore, these findings necessitate further in vitro and in vivo experimental validation to confirm their biological and clinical significance.

22. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Select Intestinal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
  6. Show and save a population bar plot of minor cell types.
  7. Show and save a population bar plot of T cell subsets.
  8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save a population bar plot of macrophage subsets.
  10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  11. Select Intestinal Epithelial cells, show their ploidy populations as a bar plot, and save the result.
  12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cells, Fibroblasts, Macrophages, T cells, B cells, Dendritic cells, Endothelial cells, ILC, Mast cells, NK cells, Plasma cells, and Smooth muscle cells. Select at most 80 cell-cell interactions per group.
  13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
  14. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
  15. Show marker expressions for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
  16. Show marker expressions for Fibroblasts in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  17. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  18. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  19. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot.
  20. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
Top